Amgen Rockville, 9201 Corporate Blvd, Suite 400, Rockville, MD 20850, United States.
Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25.
The immune system, and in particular T cells, can be harnessed to treat cancer. Several bispecific T cell engaging antibodies of the BiTE® format are in early or late-stage clinical development. These small recombinant antibody constructs effectively trigger killing of cancer cells by temporarily attached, polyclonal T cells. Blinatumomab, a CD19/CD3-bispecific BiTE® antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patients. Three additional BiTE antibodies directed against surface target antigen expressed on solid tumors are being evaluated in phase I clinical trials. Alternative approaches to direct polyclonal T cells to kill cancer cells are under intense investigation.
免疫系统，尤其是 T 细胞，可以被利用来治疗癌症。几种双特异性 T 细胞衔接抗体（BiTE® 格式）处于早期或晚期临床开发阶段。这些小型重组抗体构建物通过暂时附着的多克隆 T 细胞有效地触发癌细胞的杀伤。blinatumomab，一种 CD19/CD3 双特异性 BiTE® 抗体，在 B 细胞白血病和淋巴瘤患者中表现出很高的临床活性。另外三种针对实体瘤表面靶抗原的 BiTE 抗体正在进行 I 期临床试验评估。直接将多克隆 T 细胞导向杀伤癌细胞的替代方法正在深入研究中。
